Cutaneous T Cell Lymphoma
40
13
15
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.5%
1 terminated out of 40 trials
92.9%
+6.4% vs benchmark
10%
4 trials in Phase 3/4
23%
3 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (40)
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
Photopheresis in Early-stage Mycosis Fungoides
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)
Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment